Research ArticleAccepted Article
Intra-articular glucocorticoid injection as second-line treatment for Lyme arthritis in children
Daniel B. Horton, Alysha J. Taxter, Amy L. Davidow, Brandt Groh, David D. Sherry and Carlos D. Rose
The Journal of Rheumatology March 2019, jrheum.180829; DOI: https://doi.org/10.3899/jrheum.180829
Daniel B. Horton
From the Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research; Department of Biostatistics – Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center; Department of Pediatrics, Penn State Milton S. Hershey Medical Center; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania; Department of Pediatrics, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers F32-AR066461, L40-AR070497, and K23-AR070286, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32-HD064567. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Horton has received grant funding from Bristol-Myers Squibb for research unrelated to the present study. Dr. Rose has received grant funding from GSK for research unrelated to the present study. The other authors have no potential conflicts to disclose. Address correspondence to Daniel B. Horton, MD, MSCE 112 Paterson St, New Brunswick, NJ 08901. E-mail: daniel.horton@rutgers.edu.
Alysha J. Taxter
From the Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research; Department of Biostatistics – Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center; Department of Pediatrics, Penn State Milton S. Hershey Medical Center; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania; Department of Pediatrics, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers F32-AR066461, L40-AR070497, and K23-AR070286, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32-HD064567. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Horton has received grant funding from Bristol-Myers Squibb for research unrelated to the present study. Dr. Rose has received grant funding from GSK for research unrelated to the present study. The other authors have no potential conflicts to disclose. Address correspondence to Daniel B. Horton, MD, MSCE 112 Paterson St, New Brunswick, NJ 08901. E-mail: daniel.horton@rutgers.edu.
Amy L. Davidow
From the Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research; Department of Biostatistics – Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center; Department of Pediatrics, Penn State Milton S. Hershey Medical Center; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania; Department of Pediatrics, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers F32-AR066461, L40-AR070497, and K23-AR070286, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32-HD064567. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Horton has received grant funding from Bristol-Myers Squibb for research unrelated to the present study. Dr. Rose has received grant funding from GSK for research unrelated to the present study. The other authors have no potential conflicts to disclose. Address correspondence to Daniel B. Horton, MD, MSCE 112 Paterson St, New Brunswick, NJ 08901. E-mail: daniel.horton@rutgers.edu.
Brandt Groh
From the Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research; Department of Biostatistics – Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center; Department of Pediatrics, Penn State Milton S. Hershey Medical Center; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania; Department of Pediatrics, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers F32-AR066461, L40-AR070497, and K23-AR070286, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32-HD064567. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Horton has received grant funding from Bristol-Myers Squibb for research unrelated to the present study. Dr. Rose has received grant funding from GSK for research unrelated to the present study. The other authors have no potential conflicts to disclose. Address correspondence to Daniel B. Horton, MD, MSCE 112 Paterson St, New Brunswick, NJ 08901. E-mail: daniel.horton@rutgers.edu.
David D. Sherry
From the Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research; Department of Biostatistics – Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center; Department of Pediatrics, Penn State Milton S. Hershey Medical Center; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania; Department of Pediatrics, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers F32-AR066461, L40-AR070497, and K23-AR070286, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32-HD064567. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Horton has received grant funding from Bristol-Myers Squibb for research unrelated to the present study. Dr. Rose has received grant funding from GSK for research unrelated to the present study. The other authors have no potential conflicts to disclose. Address correspondence to Daniel B. Horton, MD, MSCE 112 Paterson St, New Brunswick, NJ 08901. E-mail: daniel.horton@rutgers.edu.
Carlos D. Rose
From the Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research; Department of Biostatistics – Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center; Department of Pediatrics, Penn State Milton S. Hershey Medical Center; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania; Department of Pediatrics, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers F32-AR066461, L40-AR070497, and K23-AR070286, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number T32-HD064567. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Horton has received grant funding from Bristol-Myers Squibb for research unrelated to the present study. Dr. Rose has received grant funding from GSK for research unrelated to the present study. The other authors have no potential conflicts to disclose. Address correspondence to Daniel B. Horton, MD, MSCE 112 Paterson St, New Brunswick, NJ 08901. E-mail: daniel.horton@rutgers.edu.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Intra-articular glucocorticoid injection as second-line treatment for Lyme arthritis in children
Daniel B. Horton, Alysha J. Taxter, Amy L. Davidow, Brandt Groh, David D. Sherry, Carlos D. Rose
The Journal of Rheumatology Mar 2019, jrheum.180829; DOI: 10.3899/jrheum.180829